Resistant hypertension (RHTN) includes patients whose blood pressure (BP) is controlled with the use of four or more antihypertensive medications, and is referred to as 'controlled resistant hypertension' (CRH). While specifically comparing patients with CRH and uncontrolled resistant hypertension (UCRH), we hoped to identify distinguishing characteristics that would provide insight into factors contributing to resistance to antihypertensive therapies. RHTN patients were identified as controlled (CRH, n ¼ 43) or uncontrolled (UCRH, n ¼ 47). No statistical differences were observed between the CRH and UCRH subgroups with respect to age and gender. The body mass index, aldosterone-renin ratio and pulse wave velocity (PWV) were significantly higher in UCRH patients. Although both subgroups showed increased cardiac mass, left ventricular mass index was significantly higher in UCRH compared with CRH patients. Multivariate linear regression analysis indicated that PWV was significantly dependent on age in both UCRH and CRH patients; however, the influence of ageing was more pronounced in the former subgroup. Older age, greater vascular stiffness, higher aldosterone levels and greater left ventricular hypertrophy were significantly associated with lack of BP control in patients with RHTN. These findings suggest important possibilities in terms of preventing and better treating RHTN.
Introduction
Resistant hypertension (RHTN) is defined as blood pressure (BP) that remains above the desired level (140/90 mm Hg), in spite of the concurrent use of three antihypertensive agents of different classes. Ideally, one of the three agents should be a diuretic, and all agents should be prescribed at optimal doses. This revised definition includes a subgroup of resistant hypertensive patients whose BP is controlled with the use of four or more antihypertensive medications, and are referred to as having 'controlled resistant hypertension' (CRH). 1 This designation may serve to be useful in terms of better categorizing RHTN with regard to aetiology and prognosis. In the former case, an important clinical question is whether there are mechanistic differences that distinguish CRH from uncontrolled resistant hypertension (UCRH).
RHTN is frequent in all ages, but is more prevalent in elderly patients. In the Framingham study, the characteristic that was most strongly predictive of uncontrolled hypertension was older age with less than 25% of subjects 475 years of age having BP controlled to the desired level. 2 Interestingly, a recent study demonstrated an interaction between plasma aldosterone levels and age, with the effects of aldosterone on ambulatory BP becoming more pronounced with increasing age. 3 It is very well known that ageing is associated with structural and functional changes of the arterial system. These changes contribute to the increase in arterial stiffness that accompanies ageing. 4 In addition to arterial stiffening, the left ventricle itself becomes stiff, representing perhaps a compensatory response to maintain cardiac output as the peripheral resistance increases. This is particularly notable in hearts that develop left ventricular hypertrophy (LVH), a common occurrence in the elderly, particularly those having hypertension. 5 Putative mechanisms for obesity-related hypertension include increased activity of the sympathetic nervous, stimulation of the renin-angiotensin-aldosterone system, impaired endothelial function and reduced urinary sodium excretion. 6 These mechanisms underlie the concept that obesity and RHTN are linked through hyperaldosteronism, and that aldosterone has a significant role in the pathogenesis of metabolic syndrome and RHTN. 7 A growing body of evidence indicates that cardiovascular and renal abnormalities associated with insulin resistance are mediated in part by aldosterone functioning on the mineralocorticoid receptor. Thus, aldosterone excess has detrimental metabolic effects that likely contribute to metabolic syndrome and endothelial dysfunction, which in turn contribute to the development of RHTN, as well as to cardiovascular disease and chronic kidney disease. 7 A study of 88 consecutive patients with RHTN reported a 20% incidence of primary aldosteronism, defined as plasma renin activity (PRA) o1.0 ng ml À1 h À1 and urinary aldosterone concentration 412 mg per 24 h during high sodium intake (urinary sodium excretion 4200 mEq per 24 h). 8 Consistent with these findings, other medical centres have reported a prevalence of primary aldosteronism of 17%-22% in RHTN patients. 9, 10 High plasma aldosterone concentrations (PACs) lead to vascular remodelling of small and large arteries causing collagen synthesis, which results in increased arterial stiffness and an elevation of BP. 11 Thus, emerging data suggest that ageing, obesity, arterial stiffness, cardiac hypertrophy and hyperaldosteronism are not only associated with RHTN but may also interact to have an important role in causing RHTN. Comparing patients with CRH and UCRH, the aim of this study is to determine whether these biological factors contribute to resistance antihypertensive therapies.
Methods

Patient population
A total of 123 consecutive subjects were referred to our center as RHTN patients. 12 All patients had a complete case history, and underwent a physical examination, electrocardiography and laboratory tests. Patients with secondary forms of hypertension, impaired renal function, ischemic heart disease, liver disease, stroke, peripheral vascular disease, dyslipidemia, diabetes, smokers or any other major diseases were excluded. Patients were submitted to investigation with included adherence to treatment [13] [14] [15] and clinical optimization of antihypertensive therapy. 12 Ambulatory BP monitoring (Spacelabs 90207, Spacelabs Inc, Redmon, WA, USA) was used only to exclude pseudoresistanse to hypertensive treatment and as an auxiliary method to characterize UCRH and CRH. After a 6-month period (five to six visits), 90 individuals were classified as being RHTN patients. They were divided into two groups: uncontrolled (UCRH, n ¼ 47) and controlled (CRH, n ¼ 43) resistant hypertensives.
This study was approved by the Research Ethics Committee of the State University of Campinas, Sao Paulo, Brazil. All participants were aware of the investigative nature of the study, and provided informed written consent before enrolling in the study.
Study design
A total of 90 patients with RHTN were evaluated. Guidance was provided on the control of dietary salt, which was confirmed by the measurement of urinary sodium excretion. None of the patients were on spironolactone therapy.
All patients were submitted to evaluations of office BP, pulse wave velocity (PWV), echocardiography, PRA and PAC.
Laboratory assessment
Baseline blood samples for the measurement of PRA and PAC were collected at 08:00 hours after overnight fasting. During this time, the volunteers rested in the supine position for 8 h, followed by 1 h in an upright position in an air-conditioned room (22-24 1C) . PRA was measured by a commercial laboratory (Mayo Clinic Laboratories, Rochester, Minnesota, USA) using standard techniques. PRA levels were measured by radioimmunoassay.
Office BP measurements
With the patients in a seated position, BP level after resting for 5 min and office BP level were obtained according to American Heart Association. 12 Office BP was measured twice using a digital automatic blood pressure monitor (OMRON Healthcare Inc., Bannockburn, IL, USA). 16 BP was considered the mean of the two readings. Pulse pressure was calculated as systolic BPÀdiastolic BP.
Aortic PWV measurement Aortic PWV was measured by the foot-to-foot velocity method with the patients in a supine position, with a previously validated Complior SP equipment and software (Artech-Medical, Paris, France). 17 Waveforms were obtained transcutaneously using the right common carotid and femoral arteries simultaneously during a minimum period of 10-15 s. Time delay (t) was measured between the two waveforms, and the distance (D) covered by the waves was measured directly between the femoral recording site and the supra-sternal notch minus the distance from the supra-sternal notch to the carotid recording site. PWV was calculated as D (m)/t (s). Three consecutive readings were obtained, and the PWV is reported as the mean.
Echocardiography
Measurements of the dimensions of the left ventricle were taken using the American Society of Echocardiography recommendations 18 using two-dimensional targeted M-mode echocardiography. Left ventricular (LV) mass was calculated by the recommended American Society of Echocardiography formula. 19 Left ventricular mass index (LVMI) was calculated by dividing LV mass by the body surface. Echocardiography measurements were evaluated by two blinded investigators.
Statistical analysis
The Statistical Analysis System, version 8.02 (SAS Institute Inc., Cary, NC, USA), was used for all statistical analyses. All values are expressed as mean ± s.d. Normality of distribution was assessed by the Kolmogorov-Smirnov test, and the variable PWV with skewed distribution was analysed after logarithmic transformation. Significant differences between the study subgroups were determined using the Student independent samples t-test, and correlation was expressed by Pearson's correlation coefficient. Relationship between age and subgroups of hypertensives with the numerical values of variables was investigated by multiple regressions analysis. The study also included univariate and multivariate analyses, with stepwise criterion for variable selection, for studying the relationship of factors of interest with the values of PWV in each subgroup (CRH and UCRH). P-values o0.05 were considered to indicate statistical significance.
Results
CRH patients received a mean of 4.3 medications daily, and the most frequently prescribed medications were diuretics (90.1%), b-blockers (46.9%), angiotensin-converting enzyme inhibitors (30.6%), angiotensin II receptor blockers (31.0%) and calcium channel blockers (28.1%); UCHR patients received a mean of 5.1 medications daily with the prescribed medications being diuretics (95.0%), b-receptors blockers (53.0%), angiotensin-converting enzyme inhibitors (25.2%), angiotensin II receptor blockers (79.9%), calcium channel blockers (81.7%) and centrally acting antiadrenergic agents (5.4%) and a 1 -receptors blockers (3.2%).
The general characteristics of the study groups are listed in Table 1 . No statistical differences were observed between the CRH and UCRH subgroups with respect to age and gender. The mean ages were 56 and 59 years in CRH and UCRH patients, respectively. Women made up 62 and 65% of the patients in these groups. Body mass index was found to be higher in UCRH patients.
Biochemical test results were very similar for both groups, except for PRA and PAC ( Table 1) . The aldosterone-renin ratio was significantly higher in UCRH patients. The prevalence of aldosteronerenin ratio of more than 20 was 21.3% (10 patients) and 4.7% (2 patients) in the UCRH and CRH subgroups, respectively.
As expected, higher systolic and diastolic BP levels were found in UCRH individuals (Table 2) . Further, pulse pressure was higher in this subgroup. 
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Although both subgroups showed LV hypertrophy, LVMI was significantly higher in UCRH than in CRH patients (Figure 1 ).
The UCRH subgroup had a higher mean PWV than the CRH subgroup (Table 2) . Multivariate linear regression analysis showed that PWV was significantly dependent on age in RHTN patients (UCRH vs CRH), with higher values for the older and UCRH patients (Figure 2 ).
Although this study was not designed to test this hypothesis, it is of interest that, considering all RHTN subjects, univariate linear regression analysis showed that PAC correlated with PWC only in patients over 60 years of age (Figure 3) . Unfortunately, the small sample size did not allow this interpretation in the two subsets of RHTN patients.
Discussion
The current study has yielded several important findings. Higher body mass index, increased vascular stiffness, higher plasma aldosterone levels and greater LVH are identified as distinguishing characteristics of patients with uncontrolled vs controlled RHTN. By multivariate analysis, PWV is shown to be dependent on age in both UCRH and CRH patients, although the influence of ageing was more important in the former. Finally, by univariate analysis, PAC correlates with PWV only in subjects with RHTN who are 460 years of age. These findings suggest several important mechanisms that may underlie the development of RHTN.
Stiffening of large arteries seems to be an inevitable consequence of the normal ageing process, such that age is the most important determinant of arterial stiffness. 20, 21 As the patients in the current evaluation were not as old as patients in previous studies of RHTN, and because they did not vary widely in age, we were able to isolate ageing from other factors that might have contributed to the uncontrolled group being more resistant to treatment. In the current analysis, we demonstrated that PWV is significantly dependent on age in both UCRH and CRH, but with the influence of ageing being more pronounced in the first subgroup. Moreover, PAC correlates with PWV only in the 460-year-old RHTN subjects. Overall, these results suggest that exacerbation of age-related increases in vascular stiffness, attributable in part to more pronounced effects of aldosterone on vascular stiffening, contributes to the likelihood of not being able to achieve BP control.
Obesity is one of the most common characteristics of patients with RHTN. In the current study, UCRH presented a higher body mass index and higher PAC compared with CRH. Taken together, these results support the concept that obesity and RHTN are linked by hyperaldosteronism. A growing body of evidence suggests that adipose tissue releases factors that stimulate aldosterone secretion, leading to excessive adrenal aldosterone production. In vitro studies have demonstrated that human adipocytes produce an as-yet-unidentified mineralocorticoidreleasing factor that stimulates adrenal aldosterone production by means of paracrine or endocrine mechanisms. 22, 23 An epoxy-keto derivative of linoleic acid (a common free fatty acid) has been identified as a potent stimulus of aldosterone release and has been shown to be increased in obese individuals. 23 Oxidation of linoleic acid to form this derivative suggests that oxidative stress drives the production of this aldosterone-stimulating free fatty acid. The elevated plasma aldosterone levels in turn induce inflammation, oxidative stress, fibrosis, insulin resistance and endothelial dysfunction. [24] [25] [26] These maladaptive processes are hypothesized to contribute to the development of a hypertensive state that is relatively resistant to pharmacological therapy. 27 These mechanisms are likely to be relevant to our results, which showed that UCRH is characterized by both higher aldosterone levels and higher body weight. In addition, the greater arterial stiffness and LVH observed in patients with UCRH are likely also attributable, at least in part, to the greater aldosterone excess that was present in this subgroup.
In the current study, arterial stiffness was clearly more prominent in UCRH. Poorly controlled hypertension undoubtedly leads to progressive vascular damage. This effect sets up a vicious cycle during which increasing vascular stiffness leads to increase in BP, which, in turn, contributes to further arterial stiffing. This sets the stage for the progressive worsening of hypertension and an increasing need for more and more BP medications. 28 Accordingly, the current data support the hypothesis that the progression from early stages of hypertension to severe and difficult to control hypertension is characterized by progressive large arterial rigidity and LVH. 29, 30 Recognition of this progression is important clinically as it may allow indexing of vascular stiffness and LV mass to facilitate early identification of patients at risk of developing RHTN. If so, early intervention with effective lifestyle changes and appropriate pharmacological agents may slow or even prevent progression to development of RHTN.
In our study, as the mean age was similar in patients with CRH and UCRH, the higher PWV and LVH in the latter group cannot be attributed solely to older age. As would be expected, PWV was significantly related to age in both subgroups, but the influence of ageing was more pronounced in the UCRH subgroup. Although there are undoubtedly multiple reasons for the observed enhanced effect of ageing on vascular stiffness in the UCRH group, the current data do implicate greater aldosterone excess as a probable contributing factor. In this study, PAC correlates with PWV only in 460-year-old RHTN subjects. In another study, Pimenta et al. 3 showed an interaction between aldosterone and age, with the effects of aldosterone on ambulatory BP becoming more pronounced with increasing age. The AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm, a large-scale randomized, controlled study of BP-lowering therapy, showed that the best predictor for the response of spironolactone on DPB was subjects older than 60 years, 31 suggesting an important role of aldosterone in hypertension of the elderly. These combined results suggest to us that the effects of ageing on vascular stiffness and the increased risk of RHTN is mediated in part by aldosterone
The greater vascular stiffness and ventricular hypertrophy were not prevented by angiotensin II receptor blockers and calcium channel blockers used by the majority of UCRH patients (about 80% of these individuals). This could be explained by previous findings of our group, which showed that combined therapy with an ACE inhibitor þ angiotensin II receptor blocker, as well as the use of a thiazide-type diuretic alone, can induce aldosterone escape in mildly and moderately hypertensive patients after 12 weeks of treatment. The clinical extrapolation of these results is that this escape could contribute to target organ damage in hypertensive subjects. 32 Moreover, this observation suggests a pivotal role for mechanical forces over other mechanisms, such as those related to activation of the renin-angiotensin system and calcium channels in RHTN patients. Structural and mechanical abnormalities leading to large artery stiffening 33 and resistance artery narrowing 34 are two of the key features associated with hypertension. Both are known to contribute to the maintenance of hypertension, as well as to associated cardiovascular complications. Recently, we compared LV hypertrophy in RHTN and controlled hypertensive subjects. We found that LV hypertrophy and diastolic dysfunction were worse in the RHTN group, and were associated with higher aldosterone plasma concentrations. We concluded that aldosterone might be responsible for the heart damage found in the RHTN group. 35 In conclusion, we demonstrate that older age, higher aldosterone levels, greater arterial stiffness and more severe LV hypertrophy characterize patients with uncontrolled RHTN compared with patients with controlled RHTN. Plasma aldosterone was significantly higher in UCRH subjects, and correlates with PWV only in over 60-year-old RHTN subjects, suggesting that excess aldosterone exacerbates age-induced vascular stiffening, leading to hypertension that is more difficult to control. Obesity was associated with higher PAC and parameters were higher in the UCRH patients.
Taken together, these findings suggest that higher body weight, greater LVH, increased arterial rigidity and higher aldosterone levels contributed to the uncontrolled group being more resistant to antihypertensive treatment. These findings suggest important possibilities in terms of preventing and better treating RHTN. Increased vascular stiffness, development of LVH and higher aldosterone levels are associated with failure to achieve BP control. Early identification of these risk factors may allow for prevention of RHTN, with rigorous lifestyle changes and early intensive pharmacological therapies. Once present, these risk factors may also predict a favourable response to targeted therapies, such as with aldosterone antagonists, even before RHTN is fully manifest. Prospective clinical assessments of such diagnostic and treatment strategies are needed to test for such benefit in this high-risk group.
